Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.47 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.47 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.47 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.44 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.44 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.44 |
| ▸ | PTGER3 | P43115 | 2/20 | 0.44 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.42 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2990732 | 0.89 | AKR1B1 (0.52) | PTGDR2PTGS1FOLH1PDCD1CD274 | |
| SCHEMBL30688324 | 0.89 | PTGDR2 (0.44) | PTGDR2PTGS1FOLH1AKR1B1PTGER1 | |
| Bicarbonate SCHEMBL28365018 | 0.86 | FOLH1 (0.50) | PTGDR2FOLH1PDCD1CD274KMT2A | |
| SCHEMBL5381774 | 0.85 | AKR1B1 (0.52) | PTGDR2PTGS1FOLH1PDCD1CD274 | |
| SCHEMBL1919745 | 0.85 | DPP4 (0.56) | PTGDR2PTGS1FOLH1PDCD1CD274 | |
| SCHEMBL29101386 | 0.85 | PTGS1 (0.46) | PTGDR2PTGS1KMT2AAKR1B1ABCC4 | |
| Acetic Acid SCHEMBL28455812 | 0.84 | FOLH1 (0.49) | PTGDR2FOLH1PDCD1CD274KMT2A | |
| SCHEMBL473270 | 0.83 | PDCD1 (0.50) | FOLH1PDCD1CD274KMT2APTGER1 | |
| SCHEMBL509798 | 0.83 | AKR1B1 (0.54) | KMT2AAKR1B1TDP1PTGS2GAA | |
| SCHEMBL27956482 | 0.83 | CD274 (0.47) | FOLH1PDCD1CD274KMT2APTGER1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2252299-B1 | FUSED PYRIDONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME (US) | 2014-03-19 | — | — | EP | disclosed |
| US-8022215-B2 | Fused pyridone M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2011-09-20 | — | — | US | disclosed |
| US-20100324088-A1 | Fused Pyridone M1 Receptor Positive Allosteric Modulators | MERCK SHARP & DOHME CORP. (US) | 2010-12-23 | — | — | US | disclosed |
| EP-2252299-A1 | FUSED PYRIDONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | Merck Sharp & Dohme Corp. (US) | 2010-11-24 | — | — | EP | disclosed |
| WO-2009102588-A1 | FUSED PYRIDONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK & CO., INC. (US) | 2009-08-20 | — | — | WO | disclosed |
| EP-0593192-B1 | Chromogenic composition for use in pressure-sensitive record material | WIGGINS TEAPE GROUP LTD (GB) | 1997-03-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324088-A1 | Fused Pyridone M1 Receptor Positive Allosteric Modulators | CHRM1, CHRM2, CHRM4 | PTGDR2 160/4885PTGS1 770/4885FOLH1 4445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.